Borui Pharmaceuticals: BGM0504 Tablets for Weight Loss Achieves Positive Results in Phase I Clinical Trial

K-LinePoet · 2026-03-27T23:25:06+00:00

Borui Pharmaceuticals announced that its developed BGM0504 tablets achieved positive results in Phase I clinical trials in China and the United States, with participants experiencing an average weight loss of 1.04% to 8.2%. Due to good safety and preliminary efficacy data, BGM0504 will continue into Phase II clinical studies.

K-LinePoet

2026-03-27 23:25:06

Abstract generation in progress

Notice: Recently, the company’s independently developed BGM0504 tablets achieved positive results in Phase I clinical trials conducted in both China and the United States for the treatment of overweight/obesity in adults. In the Chinese Phase I clinical trial, a total of 75 participants were enrolled and all completed the trial, with no serious adverse events occurring, and an average weight reduction of 1.04% to 5.56%. In the U.S. Phase I study, a total of 80 participants were enrolled, and a dose-dependent weight loss effect was preliminarily observed, with weight-loss ranges of 2.7% to 8.2%. Based on good safety and tolerability, as well as preliminary pharmacokinetic and efficacy data, these results support the continued development of BGM0504 as a potential once-daily oral treatment for overweight or obesity in subsequent Phase II clinical studies.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes